Impact of Minimal Residual Disease, Detected by Flow Cytometry, on Outcome of Myeloablative Hematopoietic Cell Transplantation for Acute Lymphoblastic Leukemia

Table 2

MRD after HCT in 17 patients who were MRD-positive before day 50 post-HCT.

Patient	Days and values of MRD (%)											Day of relapse	Day of death	Day of last contact	Treatment for MRD
1	32	80										144	164		None
	0.01	0.03
2	27	55	76									173	337		None
	0.004	0.01	0.0
3	32	48	81	109	147	181	222	732	930	1294	1428	N/A	N/A	1707	Rapid IS taper
	0.03	0.1	0.18	0.07	0.10	0.02	0.00	0.00	0.00	0.00	0.00
4	28	46	49	60	62	74	82	139	145	168		199	237		Rapid IS taper/DLI
	0.3	0.5	0.019	0.5	0.13	0.00	0.00	0.15	0.1	1.8
5	33	56	80	357								N/A	N/A	1172	Rapid IS taper
	0.009	0.008	0.001	0.00
6	28	42	56	82	147	377						N/A	N/A	1001	Rapid IS taper
	0.02	0.02	0.04	0.04	0.00	0.00
7	28	63	77									N/A	N/A	726	None
	0.0014	0.005	0.00
8	27	46	81									81	156		Imatinib
	0.15	0.02	6.5
9	33	48	82									N/A	N/A	149	None
	0.04	0.00	0.00
10	44											65	90		None
	0.04
11	28	35										N/A	39		None
	0.8	0.0
12	28	35	61	88	347							347	629		None
	0.1	0.06	0.04	0.07	7.3
13	21	37	55	83	355							N/A	N/A	579	None
	0.00	0.03	0.00	0.00	0.00
14	41											61	65		None
	0.04
15	28	56	81									152	N/A	265	Rapid IS taper/Dasatinib
	0.3	0.02	0.02
16	28	43	85									N/A	N/A	134	None
	0.002	0.00	0.00
17	29	57	84									N/A	N/A	87	None
	0.003	0.001	0.002

IS: immunosuppression.